MG
IGMS

Michael Gelband’s IGM Biosciences IGMS Stock Holding History

Michael Gelband’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-71,503
Closed -$491K – 1821
2024
Q2 		$491K Buy
71,503
+51,180
+252% +$438K ﹤0.01% 1212
2024
Q1 		$196K Buy
+20,323
New +$236K ﹤0.01% 1358
2023
Q4 		– Sell
-453,898
Closed -$3.79M – 1732
2023
Q3 		$3.79M Buy
+453,898
New +$3.85M 0.04% 449
2023
Q2 		– Sell
-59,650
Closed -$820K – 2037
2023
Q1 		$820K Buy
59,650
+12,570
+27% +$260K 0.01% 1204
2022
Q4 		$801K Buy
47,080
+21,595
+85% +$432K 0.01% 1019
2022
Q3 		$580K Buy
+25,485
New +$515K 0.01% 1315
2022
Q2 		– Sell
-10,728
Closed -$287K – 2154
2022
Q1 		$287K Buy
10,728
+1,698
+19% +$31.6K ﹤0.01% 1780
2021
Q4 		$265K Buy
9,030
+3,903
+76% +$194K ﹤0.01% 1711
2021
Q3 		$337K Sell
5,127
-1,666
-25% -$127K ﹤0.01% 1570
2021
Q2 		$565K Buy
6,793
+391
+6% +$29K 0.01% 1306
2021
Q1 		$491K Buy
+6,402
New +$583K 0.01% 1381
2020
Q4 		– Sell
-4,295
Closed -$317K – 2139
2020
Q3 		$317K Buy
+4,295
New +$254K 0.01% 1254
2020
Q2 		– Sell
-29,834
Closed -$1.68M – 1887
2020
Q1 		$1.68M Buy
+29,834
New +$1.31M 0.09% 213

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's IGMS Position: Q3 2024 in Review

Michael Gelband sold out of IGM Biosciences (IGMS) in Q3 2024, closing a stake of 71,503 shares — an estimated $491K sold.

Michael Gelband first reported a position in IGMS in Q1 2020 and held it in 13 quarters. The position peaked at $3.79M in Q3 2023. 72 funds tracked by Wall St. Rank hold IGMS as of Q3 2024.

  • Michael Gelband reported no remaining IGM Biosciences position as of Q3 2024 after selling out during the quarter.
  • Michael Gelband sold 71,503 IGM Biosciences shares in Q3 2024, an estimated $491K.
  • Michael Gelband first reported a position in IGM Biosciences in Q1 2020 and held it in 13 quarters.
  • Michael Gelband's IGM Biosciences position peaked at $3.79M in Q3 2023.
  • 72 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2024.

Based on ExodusPoint Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.